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Abstract In Alzheimer's disease, tau protein becomes hyper-
phosporylated, which can contribute to neuronal degeneration.
However, the implicated protein kinases are still unknown. Now
we report that lithium (an inhibitor of glycogen synthase kinase-
3) causes tau dephosphorylation at the sites recognized by
antibodies Tau-1 and PHF-1 both in cultured neurons and in vivo
in rat brain. This is consistent with a major role for glycogen
synthase kinase-3 in modifying proline-directed sites on tau
protein within living neurons under physiological conditions.
Lithium also blocks the Alzheimer's disease-like proline-directed
hyperphosphorylation of tau protein which is observed in neurons
treated with a phosphatase inhibitor. These data raise the
possibility of using lithium to prevent tau hyperphosphorylation
in Alzheimer's disease.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
Alzheimer's disease (AD) comprises a group of dementias
characterized by certain histopathological hallmarks which
include the presence of amyloid plaques, neuro¢brillary tan-
gles and dystrophic neurites, as well as the loss of neurons and
synapses in patients' brains. At an ultrastructural level, micro-
tubules disappear and aggregates of paired helical ¢laments
(PHF), which are mainly constituted by a modi¢ed form of
the microtubule-associated protein tau [1^3], accumulate with-
in dystrophic neurites and neuro¢brillary tangles. Hyperphos-
phorylation of tau is an early event in the course of AD and
may precede the disruption of the microtubule cytoskeleton
[4] and the formation of PHF-tau [5]. Thus, the study of the
regulation of tau protein phosphorylation in neurons is im-
portant to understand the neuro¢brillary degeneration in AD.
Current evidence suggests that tau protein has a key role in
the stabilization of microtubules within neurites, particularly
within axons where it is most abundant [6]. In vitro analyses
have demonstrated that phosphorylation a¡ects the ability of
tau to stabilize microtubules [7]. Tau phosphorylation is there-
fore hypothesized to control microtubule dynamics during
neurite growth and maturation. Indeed, embryonic and neo-
natal tau protein is much more heavily phosphorylated than
adult tau [8^11]. Decreased tau phosphorylation after neuro-
nal maturation may be due to down-regulation of protein
kinases and up-regulation of phosphatases, and could favor
axonal stabilization. Aberrant tau hyperphosphorylation in
AD may result from phosphatase down-regulation [10,12]
and lead to microtubule disassembly [4].
The sites on tau protein which become phosphorylated in
vivo have been identi¢ed [13]. Half of them correspond to
serine or threonine adjacent to proline residues, which are
targeted in vitro by a variety of proline-directed protein kin-
ases such as cyclin-dependent kinases (CDK), mitogen-acti-
vated protein kinases (MAPK) and glycogen synthase kinases
3K and 3L (GSK-3K,L). However, the kinases that actually
phosphorylate tau within living neurons have not been deter-
mined yet. This issue is crucial, as a speci¢c kinase inhibitor
might be useful to block tau hyperphosphorylation in AD.
In this report we describe that lithium inhibits site-speci¢c
AD-like tau phosphorylation in living neurons. The state of
tau phosphorylation was inferred from its electrophoretic mo-
bility and its immunoreactivity toward antibodies that recog-
nize phosphorylation-sensitive epitopes. These results are con-
sistent with an involvement of GSK-3 in neuronal tau
phosphorylation.
2. Materials and methods
2.1. Materials
Tau monoclonal antibodies: 7.51 [14] (a kind gift of Dr. C. Wis-
chik, MRC, Cambridge, UK), Tau-1 [2,15] (a kind gift of Dr. L.
Binder, MGC, IL, USA), 12E8 [16] (a kind gift of Dr. P. Seubert,
Athena, San Francisco, CA, USA) and PHF-1[3,17] (a kind gift of
Dr. P. Davies, Albert Einstein Coll., Bronx, NY, USA) were used.
According to the residue numbering of the longest human tau isoform
of 441 amino acids [18], antibody Tau-1 recognizes tau protein only
when serines 195, 198, 199 and 202 are dephosphorylated [15] Anti-
body 12E8 reacts with tau when serine 262 is phosphorylated [16].
Antibody PHF-1 recognizes tau when serines 396 and 404 are phos-
phorylated [17]. PD 098059 (2-(2P-amino-3P-methoxyphenyl)-oxana-
phthalen-4-one) [19] was purchased from RBI. Olomoucine (2-(2-hy-
droxyethylamino)-6-benzylamino-9-methylpurine) [20] was purchased
from Calbiochem. All other reagents were from Sigma.
2.2. Neuronal culture
Primary cultures of cerebellar granule neurons were prepared from
7-day-old rat pups following the procedure of Levi and colleagues [21]
with slight modi¢cations. Brie£y, trypsin-dissociated cells were plated
onto poly-L-lysine-coated plastic dishes and cultured in Neurobasal-
B27 medium (Gibco) [22] supplemented with 10% fetal bovine serum,
25 mM KCl and 1 mM glutamine. Cytosine arabinoside (10 WM) was
added to cultures 24 h after seeding to prevent non-neuronal cell
proliferation. Experiments were performed after 6^8 days in vitro.
At this stage, purity of cultures was evaluated by immuno£uorescence
with antibodies to MAP2 and GFAP. The number of glial cells was
about 2% as determined by counting cells positive for GFAP. Thus,
the cultures were close to 98% pure granule neurons.
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2.3. Animal treatment with lithium
Seven-day-old rat pups (weighing 22^25 g) were intraperitoneally
injected with 400 Wl of either 1 M LiCl or NaCl. 8 h after injection,
rats were killed by decapitation. Then, cerebral cortices and cerebella
were dissected and immediately processed as described below.
2.4. Protein preparation
Cells were harvested, washed in chilled PBS (phosphate-bu¡ered
saline), resuspended and homogenized in a bu¡er consisting of 20
mM HEPES, pH 7.4, 100 mM NaCl, 100 mM NaF, 1 mM sodium
orthovanadate, 5 mM EDTA, and protease inhibitors (2 mM PMSF,
10 Wg/ml aprotinin, 10 Wg/ml leupeptin and 10 Wg/ml pepstatin). Brain
tissue was also homogenized in the same bu¡er supplemented with
1 WM okadaic acid (which is included to block any post-mortem tau
dephosphorylation). Lysates were centrifuged at 10 000Ug for 10 min
at 4³C. The resulting supernatants were collected and their protein
contents determined by the BCA assay.
2.5. Immunoblot analysis
Samples were mixed with Laemmli's bu¡er, boiled for 3 min, sep-
arated by SDS-PAGE on 12% resolving gels and transferred to nitro-
cellulose according to standard procedures. A blocking bu¡er of 5%
non-fat powdered milk in PBS with 0.1% Tween-20 was used for all
incubations. Immunoreactive proteins were visualized by the use of a
peroxidase-conjugated anti-mouse antibody and enhanced chemilumi-
nescence detection (Amersham). Quanti¢cation of immunoreactivity
was performed by densitometric scanning. Individual tau bands may
include multiple distinct tau proteins (arising from alternative splicing
and di¡erential phosphorylation) that comigrate and were therefore
not quantitated separately. Thus, total immunoreactivity for all tau
bands was quantitated. The densitometry values obtained for blots
corresponding to the antibodies recognized phosphorylation-sensitive
epitopes (Tau-1, 12E8 and PHF-1) were normalized with respect to
the values obtained for antibody 7.51 in order to correct any deviation
in loaded amounts of protein.
3. Results
3.1. E¡ect of lithium on tau phosphorylation in cultured
neurons
Previous studies in tau-transfected non-neuronal cells have
pointed to GSK-3 as a good candidate to be responsible for
most tau phosphorylation at Ser/Thr-Pro sites [23]. Lithium
has recently been described to act as an uncompetitive and
speci¢c inhibitor of GSK-3 with an IC
50
near 2 mM in in vitro
assays [24,25]. For this reason we focused on the possible role
of this enzyme and examined the e¡ects of lithium on tau
phosphorylation in cultured neurons.
Treatment of cultured rat cerebellar granule neurons with
LiCl for 6 h results in dose-dependent site-speci¢c tau dephos-
phorylation (see Fig. 1). The great increase in Tau-1 immu-
noreactivity and the decrease in PHF-1 immunoreactivity
demonstrate that tau proteins are substantially dephosphory-
lated at these epitopes after LiCl treatment. In contrast, no
signi¢cant change in 12E8 immunoreactivity is found, which
suggests that phosphorylation at this site is unaltered by LiCl.
The fact that the electrophoretic mobility of tau proteins is
notably augmented after lithium treatment (as observed with
antibody 7.51 that recognizes a phosphorylation-independent
epitope on tau [14]) is consistent with a net dephosphorylation
of tau protein at most proline-directed sites.
Interestingly, the half maximal dephosphorylation of tau
protein in cultured neurons is observed at a lithium concen-
tration close to 2 mM, which coincides with the reported IC
50
for the inhibition of puri¢ed GSK-3 in vitro [24]. These results
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Fig. 1. Comparative e¡ects of lithium and olomoucine on tau protein phosphorylation in cultured neurons. Cells were treated with the indi-
cated concentrations of LiCl or olomoucin for 6 h. Cytoplasmic extracts were prepared, electrophoresed, blotted, and probed with antibodies
7.51, Tau-1, 12E8 and PHF-1. `C' refers to untreated (control) cells. Immunoreactivities were quantitated as described in Section 2 and showed
as normalized densitometry values (NDV) below the lanes. Numbers to the left indicate the position of molecular weight markers in kDa.
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Fig. 2. Comparative e¡ects of lithium, lithium supplemented with myo-inositol and MEK inhibitor (PD 098059) on tau protein phosphorylation
in cultured neurons. Cells were treated with 20 mM LiCl for 6 h (LiCl), with 20 mM LiCl in the presence of 50 mM myo-inositol for 6 h
(LiCl/Ino) or with 100 WM PD 098059 for 6 h (MekI). Cytoplasmic extracts were prepared, electrophoresed, blotted and probed with antibodies
7.51, Tau-1, 12E8 and PHF-1. `Control' refers to untreated cells. Immunoreactivities were quantitated as described in Section 2 and showed as
normalized densitometry values (NDV) below the lanes. Numbers to the left indicate the position of molecular weight markers in kDa.
Fig. 3. Comparative e¡ects of lithium and MEK inhibitor (PD 098059) on the okadaic acid-induced tau phosphorylation in cultured neurons.
Cells were treated with 1 WM okadaic acid for 1 h (okadaic), with 20 mM LiCl for 7 h (LiCl), with 20 mM LiCl for 6 h followed by a treat-
ment with 1 WM okadaic acid for 1 h in the presence of 20 mM LiCl (LiCl/Ok), with 100 WM PD 098059 for 7 h (MekI) or with 100 WM PD
098059 for 6 h followed by a treatment with 1 WM okadaic acid for 1 h in the presence of 100 WM PD 098059 (MekI/Ok). Cytoplasmic ex-
tracts were prepared, electrophoresed, blotted and probed with antibodies 7.51, Tau-1, 12E8 and PHF-1. `Control' refers to untreated cells.
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suggest that tau protein becomes dephosphorylated in lithium-
treated neurons as a consequence of ongoing protein phos-
phatase activity when GSK-3 is inhibited by lithium. How-
ever, the direct assay of GSK-3 inhibition by lithium in cul-
tured neurons cannot be performed with any procedure
depending on cell homogenization and GSK-3 puri¢cation
since the e¡ect of lithium is reversible [24,25].
To test for the speci¢city of the lithium e¡ect on tau phos-
phorylation, other protein kinase inhibitors were used. Fig. 1
shows that olomoucin, a potent inhibitor of cyclin-dependent
kinases [20], does not a¡ect either the electrophoretic mobility
of tau protein or its immunoreactivity to antibodies reacting
with phosphorylation-sensitive epitopes. PD 098059, an inhib-
itor of the MAPK-activating enzyme MEK that blocks stim-
ulation of MAPK and subsequent phosphorylation of MAPK
substrates [19], also fails to modify tau phosphorylation in
cultured neurons (see Fig. 2). Thus, among the protein kinase
inhibitors tested, lithium appears unique in blocking neuronal
tau phosphorylation. Lithium may also inhibit inositol mono-
phosphatase, which might cause inositol depletion [24]. To
rule out the possibility that lithium e¡ect on tau phosphory-
lation was due to inositol depletion, neurons were treated with
lithium in the presence of a high level of extracellular myo-
inositol (50 mM). As shown in Fig. 2, myo-inositol fails to
revert the lithium-induced tau dephosphorylation. Further-
more, lithium is not toxic to cultured neurons during the
time periods examined (data not shown).
These data suggest that tau phosphorylation at the Tau-1
and PHF-1 epitopes is largely due to the activity of GSK-3.
Previous observations on the co-localization of GSK-3 and
tau protein in situ in rat brain [26,27] support this view,
although the existence of another proline-directed protein kin-
ase acting on tau protein cannot be completely ruled out.
Phosphorylation of tau at the 12E8 epitope seems to be in-
dependent of GSK-3 in neurons. It is important to note that
both Tau-1 and PHF-1 epitopes contain Ser-Pro motifs and
are targets for GSK-3 whereas serine at the 12E8 epitope is
not adjacent to any Pro residue.
3.2. E¡ect of lithium on okadaic acid-induced tau
hyperphosphorylation in cultured neurons
The hyperphosphorylated state of tau protein in Alzheim-
er's disease may be due to defective dephosphorylation
[10,12]. Thus, okadaic acid, a potent phosphatase inhibitor,
has been used to induce the appearance of Alzheimer's dis-
ease-like hyperphosphorylated tau both in cultured neurons
[28] and in vivo in rat brain [29]. Given the e¤cacy of lithium
in inhibiting tau phosphorylation in cultured neurons under
physiological conditions, we checked whether okadaic acid-
induced tau hyperphosphorylation can also be prevented by
lithium.
Treatment of cultured rat cerebellar neurons with 1 WM
okadaic for 1 h leads to an Alzheimer's disease-like phospho-
rylation state of tau protein as judged from its increased im-
munoreactivity to antibodies 12E8 and PHF-1 and loss of
immunoreactivity to antibody Tau-1 (see Fig. 3). Pre-treat-
ment of cultured neurons with LiCl blocked the changes in
immunoreactivity to antibodies Tau-1 and PHF-1, without
a¡ecting the immunoreactivity to antibody 12E8. Thus, lith-
ium can e¡ectively prevent the increased phosphorylation of
tau protein which is observed at the sites recognized by anti-
bodies Tau-1 and PHF-1 when neurons are treated with oka-
daic acid. In contrast, phosphorylation at the site recognized
by antibody 12E8 is enhanced by okadaic acid irrespective of
the presence of lithium. A quanti¢cation of the observed
changes is presented in Fig. 4 to take into account the varia-
tions between experiments. It is clearly apparent that the mag-
nitude of okadaic acid-induced change in immunoreactivity is
di¡erent for the Tau-1 and PHF-1 epitopes. This may be due
to di¡erent sensitivities of these phosphorylation sites to dis-
tinct protein phosphatases. Notwithstanding this fact, lithium
is quite e¡ective in blocking hyperphosphorylation at these
epitopes.
Another kinase inhibitor (PD 098059) was used for compar-
ison and failed to signi¢cantly and consistently modify the
augmented phosphorylation of tau at the studied epitopes.
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Fig. 4. Quanti¢cation of the inhibition of the okadaic acid-induced
tau hyperphosphorylation in cultured neurons by lithium. Cytoplas-
mic extracts from treated cells were probed with antibodies 7.51,
Tau-1, 12E8 and PHF-1 as indicated in the legend to Fig. 3. Quan-
ti¢cation of immunoreactivities to antibodies Tau-1, 12E8 and PHF-
1 were performed by densitometry and normalized with respect to
the values corresponding to antibody 7.51. Shown are the mean
normalized densitometry values and the corresponding standard de-
viations from four independent experiments.
J.R. Munìoz-Montanìo et al./FEBS Letters 411 (1997) 183^188186
These data agree well with a recent report demonstrating that
okadaic acid induces tau hyperphosphorylation independently
of MAPK activation [30]. Our results indicate that this tau
hyperphosphorylation depends on GSK-3 (for the Tau-1 and
PHF-1 epitopes) and additional kinase(s) (for the 12E8 epit-
ope).
3.3. E¡ect of lithium on tau phosphorylation in vivo in rat brain
In view of the tau dephosphorylation which is observed in
lithium-treated cultured neurons, we examined if this also oc-
curs in vivo. Fig. 5 shows that intraperitoneal administration
of lithium into 7-day-old rat pups results in the dephospho-
rylation of cerebellar tau protein at the Tau-1 and PHF-1
epitopes without a¡ecting the phosphorylation at the 12E8
epitopes. These data are qualitatively similar to those found
in cultured neurons, although a less marked increase in the
electrophoretic mobility of tau protein is observed. Further
comparison between the results obtained in vivo and those
obtained with cultured neurons is di¤cult since the intra-
neuronal concentration of lithium which is attained in vivo
after intraperitoneal administration is unknown.
A more modest lithium-induced dephosphorylation is ob-
served in tau protein from neocortical tissue, particularly at
the Tau-1 epitope (see Fig. 5). This may be due to the di¡er-
ent timing of neuronal development in these two brain re-
gions. Whereas there is a prominent axonal growth in cere-
bellar granule neurons, most cortical neurons have reached a
comparatively more mature stage in 7-day-old rats. As the
phosphate turnover on tau protein diminishes after neuronal
maturation [11], the inhibition of tau phosphorylation by lith-
ium may not be immediately followed by dephosphorylation
in neocortical neurons during the short treatment employed in
this experiment. Indeed, we have observed a signi¢cant de-
crease in the lithium-induced dephosphorylation of tau pro-
tein after maturation of cultured cerebellar neurons (data not
shown). This interpretation agrees well with the block of neu-
ro¢lament protein phosphorylation without net dephospho-
rylation which has been found in lithium-treated sensory neu-
rons [31]. Interestingly, dephosphorylation at the PHF-1
epitope is much more apparent than dephosphorylation at
the Tau-1 epitope in tau from rat neocortex, which again
suggests a di¡erent sensitivity of these phosphorylation sites
to distinct protein phosphatases.
4. Discussion
Tau protein hyperphosphorylation is an early and charac-
teristic feature of Alzheimer's disease that seems to be corre-
lated with the cognitive impairment of the patients [32]. The
¢rst consequence of tau hyperphosphorylation in AD may be
the destabilization of the microtubule cytoskeleton [4]. Sup-
portive of this view is the fact that tau phosphorylation at
proline-directed sites by GSK-3 (upon co-transfection in
non-neural cells) abolishes the microtubule-stabilizing e¡ect
which is observed in tau-transfected cells [33,34]. In immature
neurons, tau phosphorylation may favor the microtubule dy-
namics which is probably required for neurite growth. A de-
creased tau phosphorylation in mature neurons might help to
attain and maintain neurite stability. The aberrant hyperphos-
phorylation of tau in AD may shift the balance toward ex-
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Fig. 5. E¡ect of lithium on the in vivo tau phosphorylation. Seven-day-old rat pups were treated with either lithium chloride (LiCl) or saline
(control) for 8 h as described in Section 2. Extracts from cerebral cortices and cerebella were prepared, electrophoresed, blotted and probed
with antibodies 7.51, Tau-1, 12E8 and PHF-1. Tau immunoreactivities from cerebellar and cortical samples were quantitated separately as de-
scribed in Section 2 and showed as normalized densitometry values (NDV) below the lanes. Numbers to the left indicate the position of molec-
ular weight markers in kDa.
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cessive microtubule depolymerization [4]. This would lead to
defective axonal transport of organelles and impaired retro-
grade axonal transport of neurotrophic factors, as well as to
alterations in neurite morphology.
Another consequence of tau hyperphosphorylation is a di-
minished susceptibility to protease digestion which results in a
decreased tau protein turnover, as it has been observed in
neuroblastoma cells treated with okadaic acid [35]. Indeed,
PHF-tau obtained from AD patient brains is quite resistant
to proteolytic cleavage unless it is previously dephospho-
rylated [36]. A reduction in the turnover of tau in patient
brains may favor the accumulation of other modi¢cations
(ubiquination, oxidation, glycation, glycosylation, proteogly-
can binding), which could eventually lead to the aggregation
of tau into PHF and be therefore responsible for the forma-
tion of neuro¢brillary tangles.
Thus, the prevention of tau hyperphosphorylation is likely
to block the disruption of the cytoskeleton and the neuro¢-
brillary degeneration occurring in AD. Here we have demon-
strated that lithium, both in cultured neurons and in vivo in
rat brain, inhibits tau phosphorylation at certain proline-di-
rected sites which become hyperphosphorylated in AD. This
suggests that GSK-3, the putative target for lithium [24,25], is
indeed implicated in tau phosphorylation in living neurons,
which extends and con¢rms all the data obtained from co-
transfection studies in non-neuronal cell lines [23,25,33,34].
Whether GSK-3 is also implicated in pathological tau hyper-
phosphorylation in AD remains to be proven. The signi¢cant
co-localization of GSK-3 with neuro¢brillary lesions in AD
patient brains [37,38] is consistent with a role of this enzyme
in tau modi¢cation in AD. If this is the case, a new window
for therapeutic intervention into AD may be opened up, since
a chronic lithium treatment similar to that prescribed for
manic-depressive patients might slow down tau hyperphos-
phorylation in the brains of patients with AD.
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